

CITATION REPORT

List of articles citing

Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial

DOI: 10.1016/j.jacc.2004.09.076

Journal of the American College of Cardiology, 2005, 45, 525-30.

Source: <https://exaly.com/paper-pdf/39443268/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
221	Prevention of sudden cardiac death: lessons from recent controlled trials. <i>Circulation Journal</i> , 2005 , 69, 625-9	2.9	18
220	Carvedilol@ antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. 2005 , 28, 165-73		20
219	Drug therapy for atrial fibrillation: where do we go from here?. 2005 , 4, 899-910		42
218	Electrophysiologic effects of carvedilol: is carvedilol an antiarrhythmic agent?. 2005 , 28, 985-90		18
217	Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). 2005 , 96, 691-5		82
216	Antiadrenergic therapy in the control of atrial fibrillation. 2005 , 10 Suppl 1, S33-43		3
215	Carvedilol in chronic heart failure: past, present and future. 2005 , 1, 723-34		3
214	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult@ Summary Article. 2005 , 112, 1825-1852		334
213	Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. 2005 , 2, 502-3		
212	Beta-Adrenergic blockers as antiarrhythmic and antifibrillatory compounds: an overview. 2005 , 10 Suppl 1, S3-S14		31
211	Ventricular arrhythmias: antiadrenergic therapy for the patient with coronary artery disease. 2005 , 10 Suppl 1, S23-31		9
210	A review of carvedilol arrhythmia data in clinical trials. 2005 , 10 Suppl 1, S59-68		9
209	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest		1915
208	Three decades of clinical trials with beta-blockers: the contribution of the CAPRICORN trial and the effect of carvedilol on serious arrhythmias. <i>Journal of the American College of Cardiology</i> , 2005 , 45, 531-2	15.1	5
207	ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1-82	15.1	1119
206	ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult@ Summary Article. <i>Journal of the American College of Cardiology</i> , 2005 , 46, 1116-1143	15.1	314
205	Atrial fibrillation: challenges and opportunities. 2006 , 22 Suppl C, 21C-26C		3

204	[Ischemic heart disease: 2005 update]. 2006 , 59 Suppl 1, 3-19		3
203	[Arrhythmias and cardiac electrophysiology: main developments in 2005]. 2006 , 59 Suppl 1, 20-30		1
202	Highlights of the Year in JACC 2005. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 184-202	15.1	5
201	The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1683-8	15.1	36
200	ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation) Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2006 , 48, e149-e246	15.1	261
199	Reducing the risk of sudden death in heart failure with beta-blockers. 2006 , 12, 734-46		32
198	ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 guidelines for the management of patients with atrial fibrillation) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. 2006 , 8, 651-745		530
197	Implantable defibrillator early after primary percutaneous intervention for ST-elevation myocardial infarction: rationale and design of the Defibrillator After Primary Angioplasty (DAPA) trial. 2006 , 152, 636-40		9
196	Meta-analysis: inhibition of renin-angiotensin system prevents new-onset atrial fibrillation. 2006 , 152, 217-22		135
195	Improving the management of patients after myocardial infarction, from admission to discharge. 2006 , 28, 1509-39		6
194	Beta blockade in the post-myocardial infarction setting: pharmacologic rationale and clinical evidence. 2006 , 9, 96-101		1
193	Sudden Death Prevention in Heart Failure: The Case of CIBIS III. 2006 , 2, 182618680600200		
192	Beta-Blockers. 2006 , 159-167		
191	Effect of combination therapy with simvastatin and carvedilol in patients with left ventricular dysfunction complicated with acute myocardial infarction who underwent percutaneous coronary intervention. <i>Circulation Journal</i> , 2006 , 70, 1269-74	2.9	9
190	Medical management of atrial fibrillation. 2006 , 8, 323-9		6
189	Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?. 2006 , 97, 1255-61		182
188	Effect of beta blockers, particularly carvedilol, on reducing the risk of events after acute myocardial infarction. 2006 , 98, 1115-9		38
187	Managing the post-myocardial infarction patient with asymptomatic left ventricular dysfunction. 2006 , 105, 95-107		5

186	Beta-Blocker Therapy for Septic Cardiac Shock: Fiction Or Realism?. 2006 , 1, 131-133		
185	Carvedilol blocks beta2- more than beta1-adrenoceptors in human heart. 2006 , 69, 128-39		25
184	Profile of carvedilol controlled-release: a new once-daily formulation of carvedilol. 2006 , 7, 2533-46		12
183	Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF Study. <i>European Journal of Heart Failure</i> , 2006 , 8, 539-46	12.3	72
182	ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in		1653
181	Prevention of atrial fibrillation onset by beta-blocker treatment in heart failure: a meta-analysis. 2007 , 28, 457-62		134
180	Uncertainty on the use of aldosterone antagonists for primary therapy for sudden cardiac death in the setting of implanted devices. 2007 , 115, 2983-9; discussion 2989		1
179	From exercise training to sudden death prevention via adrenergic receptors. 2007 , 293, H2631-3		3
178	The pharmacological response of ischemia-related atrial fibrillation in dogs: evidence for substrate-specific efficacy. 2007 , 74, 104-13		34
177	Management of atrial fibrillation in patients with heart failure. 2007 , 28, 2568-77		70
176	Delayed rhythm control of atrial fibrillation may be a cause of failure to prevent recurrences: reasons for change to active antiarrhythmic treatment at the time of the first detected episode. 2008 , 10, 21-7		98
175	Added benefit of mineralocorticoid receptor blockade in the primary prevention of sudden cardiac death. 2007 , 115, 2976-82; discussion 2982		25
174	Preemptive, but not reactive, spinal cord stimulation mitigates transient ischemia-induced myocardial infarction via cardiac adrenergic neurons. 2007 , 292, H3111-7		81
173	Drug therapy for ventricular tachyarrhythmia in heart failure. <i>Circulation Journal</i> , 2007 , 71 Suppl A, A90-6.9		9
172	Management of post-myocardial infarction patients with left ventricular systolic dysfunction. 2007 , 120, 109-20		12
171	Impact of acute beta-blocker therapy for patients with non-ST-segment elevation myocardial infarction. 2007 , 120, 685-92		32
170	beta-Adrenoceptor antagonists in elderly patients with heart failure: a critical review of their efficacy and tolerability. 2007 , 24, 1031-44		12
169	Prescription of beta-blockers in patients with advanced heart failure and preserved left ventricular ejection fraction. Clinical implications and survival. <i>European Journal of Heart Failure</i> , 2007 , 9, 280-6	12.3	55

168	Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET. <i>Journal of the American College of Cardiology</i> , 2007 , 49, 963-71	15.1	56
167	Carvedilol inhibits mitochondrial complex I and induces resistance to H ₂ O ₂ -mediated oxidative insult in H9C2 myocardial cells. 2007 , 1767, 222-32		46
166	Efficacy of drug therapy in the secondary prevention of cardiovascular disease and stroke. 2007 , 99, 1E-35E		18
165	Fighting against sudden death: a single or multidisciplinary approach. 2006 , 17, 205-10		
164	Race-based therapeutics. 2007 , 1, 108-117		
163	Electrophysiological effects of carvedilol administration in patients with dilated cardiomyopathy. 2008 , 22, 169-76		11
162	Race-based therapeutics. 2008 , 10, 276-85		15
161	Does atrial fibrillation beget ventricular fibrillation in patients with acute myocardial infarction?. 2008 , 31, 1612-9		15
160	Relation of mortality to failure to prescribe beta blockers acutely in patients with sustained ventricular tachycardia and ventricular fibrillation following acute myocardial infarction (from the VALsartan In Acute myocardial iNfarcTion trial [VALIANT] Registry). 2008 , 102, 1427-32		37
159	Sudden cardiac death and the role of medical therapy. 2008 , 50, 420-38		23
158	Atrial Fibrillation. 2008 ,		6
157	Role of drug therapy for sustained ventricular tachyarrhythmias. 2008 , 26, 405-18, vi		9
156	Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. 2008 , 126, 108-13		53
155	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. 2008 , 372, 807-16		775
154	In-hospital arrhythmias in patients with acute myocardial infarction - the relation to the reperfusion strategy and their prognostic impact. 2008 , 10, 15-25		10
153	Acute Coronary Syndrome. 2008 ,		
152	Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction. 2008 , 4, 1387-400		9
151	Carvedilol in the treatment of elderly patients with chronic heart failure. 2008 , 3, 55-70		1

150	The Role of Beta Blockers in Treating Hypertensive Patients. 2009 , 45, 75		
149	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. 2009 , 119, e391-479		1178
148	Atrial fibrillation complicating acute myocardial infarction: how should it be interpreted and how should it be treated and prevented?. 2009 , 30, 1035-7		12
147	Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. 2009 , 30, 1038-45		365
146	Realities of newer beta-blockers for the management of hypertension. 2009 , 11, 369-75		29
145	Pharmacotherapy for rhythm management in elderly patients with atrial fibrillation. 2009 , 25, 25-9		13
144	Real-world algorithms for the optimal use of drugs and devices in the patient post myocardial infarction and the future of post myocardial infarction management. 2005 , 28, 158-63		1
143	Perioperative use of beta-blockers in the elderly patient. 2009 , 27, 581-97, table of contents		5
142	Risk of ventricular arrhythmia after implantable defibrillator treatment in anxious type D patients. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 531-7	15.1	82
141	Appropriate evaluation and treatment of heart failure patients after implantable cardioverter-defibrillator discharge: time to go beyond the initial shock. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 1993-2000	15.1	53
140	Role of carvedilol controlled-release in cardiovascular disease. 2009 , 7, 483-98		12
139	Use and risk management of carvedilol for the treatment of heart failure in the community in England: results from a modified prescription-event monitoring study. 2009 , 32, 43-54		9
138	2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. <i>Journal of the</i>	15.1	1224
137	Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF. 2009 , 6, 445-51		41
136	Beta-blocker use for the stages of heart failure. <i>Mayo Clinic Proceedings</i> , 2009 , 84, 718-29	6.4	55
135	Atrial fibrillation and congestive heart failure. 2009 , 24, 29-34		31
134	Carvedilol ameliorates the decreases in connexin 43 and ventricular fibrillation threshold in rats with myocardial infarction. 2009 , 218, 121-7		13
133	QRS duration is associated with atrial fibrillation in patients with left ventricular dysfunction. 2010 , 33, 132-8		23

132	Cardiac adrenergic control and atrial fibrillation. 2010 , 381, 235-49		81
131	[Antiarrhythmic therapy with β receptor antagonists]. 2010 , 21, 222-7		1
130	Clinical management of ventricular tachycardia. 2010 , 35, 453-504		28
129	Neurohormonal Blocking Agents in the Treatment of Patients with Left Ventricular Dysfunction and Heart Failure. 2010 , 83-116		
128	Can we improve the identification of ventricular scar to guide substrate-based ventricular tachycardia ablation?. 2010 , 21, 685-7		0
127	Antiarrhythmic and Nonantiarrhythmic Drugs for Sudden Cardiac Death Prevention. 2010 , 55, 438-449		36
126	Effect of beta-blockers on the risk of atrial fibrillation in patients with acute myocardial infarction. 2010 , 65, 265-70		10
125	Influence of beta-blocker therapy on antitachycardia pacing effectiveness for monomorphic ventricular tachycardias occurring in implantable cardioverter-defibrillator patients: a dose-dependent effect. 2010 , 12, 1231-8		15
124	A review and meta-analysis of studies on the effect and timing of β blocker administration in patients with ST-segment elevation myocardial infarction. 2010 , 38, 63-8		4
123	New-onset atrial fibrillation and acute coronary syndrome. 2010 , 8, 941-8		28
122	Carvedilol ameliorates sympathetic nerve sprouting and electrical remodeling after myocardial infarction in rats. 2010 , 64, 446-50		11
121	2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the European Society of Cardiology and the Heart Rhythm Society. 2011 , 123, e269-367	15.1	645
120	Comparison of effectiveness of carvedilol versus bisoprolol for prevention of postdischarge atrial fibrillation after coronary artery bypass grafting in patients with heart failure. 2011 , 107, 215-9		16
119	Arrhythmias and vagus nerve stimulation. 2011 , 16, 147-61		45
118	Effects of high thoracic epidural anesthesia on atrial electrophysiological characteristics and sympathetic nerve sprouting in a canine model of atrial fibrillation. 2011 , 106, 495-506		21
117	Management der interventionellen Therapie von Patienten mit akutem Koronarsyndrom und Vorhofflimmern. 2011 , 5, 291-306		
116	2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. 2011 , 123, e269-367		643
115	Carvedilol and its new analogs suppress arrhythmogenic store overload-induced Ca^{2+} release. 2011 , 17, 1003-9		157

114 ¿Es posible prevenir la fibrilacion auricular y sus complicaciones?. **2012**, 23, 732-741

113 Atrial fibrillation in heart failure: an innocent bystander?. **2012**, 8, 273-80

5

112 Incidence, predictors, and 30-day outcomes of new-onset atrial fibrillation after primary percutaneous coronary intervention: insight into the RISK-PCI trial. **2012**, 23, 1-8

26

111 Atrial fibrillation in acute ST-elevation myocardial infarction: clinical and prognostic features. **2012**, 8, 281-9

17

110 A multicentre, randomized study of telmisartan versus carvedilol for prevention of atrial fibrillation recurrence in hypertensive patients. **2012**, 13, 496-503

13

109 A critical review of the use of carvedilol in ischemic heart disease. **2012**, 12, 391-401

15

108 Atrial fibrillation and mortality in patients with acute myocardial infarction: a systematic overview and meta-analysis. **2012**, 14, 601-10

44

107 [Atrial fibrillation during the first month following an acute myocardial infarction]. **2012**, 61, 32-6

106 Traditional heart failure medications and sudden cardiac death prevention: a review. **2013**, 18, 412-26

19

105 Metoprolol vs. carvedilol or carvedilol plus N-acetyl cysteine on post-operative atrial fibrillation: a randomized, double-blind, placebo-controlled study. **2013**, 34, 597-604

40

104 Impact of beta blockade therapy on long-term mortality after ST-segment elevation acute myocardial infarction in the percutaneous coronary intervention era. **2013**, 111, 457-64

60

103 Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. **2013**, 1, 21-8

97

102 Heterogeneous upregulation of apamin-sensitive potassium currents in failing human ventricles. **2013**, 2, e004713

65

101 Slow sinus heart rate as a potential predictive factor of paroxysmal atrial fibrillation in stroke patients. **2013**, 36, 120-5

3

100 Guidelines for Secondary Prevention of Myocardial Infarction (JCS 2011). *Circulation Journal*, **2013**, 77, 231-48

2.9 72

99 Management of ventricular tachycardia in heart failure. **2013**, 9, 20-5

4

98 Collaborative multicenter trials in Latin America: challenges and opportunities in orthopedic and trauma surgery. **2013**, 131, 187-92

4

97 Role of Traditional Heart Failure Medications on Sudden Cardiac Death Prevention in Patients with Cardiomyopathy. **2013**,

96	Impact of Nontraditional Antiarrhythmic Drugs on Sudden Cardiac Death. 2014 , 1121-1128		
95	2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 , 130, e344-426		754
94	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. 2014 , 130, e199-267		1016
93	2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e1-76	15.1	2768
92	Effects of carvedilol on cardiac autonomic nerve activities during sinus rhythm and atrial fibrillation in ambulatory dogs. 2014 , 16, 1083-91		3
91	Association of beta-blocker therapy at discharge with clinical outcomes in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. 2014 , 7, 592-601		56
90	Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure. 2014 , 10, 543-57		14
89	2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2014 , 64, e139-e228	15.1	1822
88	Pharmacotherapy to reduce arrhythmic mortality. 2014 , 66 Suppl 1, S113-9		1
87	Effect of antihypertensive agents on risk of atrial fibrillation: a meta-analysis of large-scale randomized trials. 2015 , 17, 701-10		32
86	Management of pace-terminated ventricular arrhythmias. 2015 , 7, 497-513		
85	The rationale and design of the Beta-blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study. 2015 , 20, 140-7		5
84	Mechanisms of new-onset atrial fibrillation complicating acute coronary syndrome. 2015 , 40 Suppl 1, 18-26		17
83	Nebivolol versus Carvedilol or Metoprolol in Patients Presenting with Acute Myocardial Infarction Complicated by Left Ventricular Dysfunction. 2016 , 25, 316-22		12
82	Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. 2016 , 69, 1167.e1-1167.e85		91
81	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2016 , 37, 2129-2200		7751
80	Carvedilol Suppresses Apoptosis and Ion Channel Remodelling of HL-1 Cardiac Myocytes Expressing E334K cMyBPC. 2016 , 66, 126-9		
79	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Journal of Heart Failure</i> , 2016 , 18, 891-975	12.3	4036

78	Long-term effect of β blocker in ST-segment elevation myocardial infarction in patients with preserved left ventricular systolic function: a propensity analysis. 2016 , 31, 441-8	12
77	Temporal trends and outcomes associated with atrial fibrillation observed during acute coronary syndrome: Real-world data from the Acute Coronary Syndrome Israeli Survey (ACSIS), 2000-2013. 2017 , 40, 275-280	15
76	Thymosin α promotes the survival and angiogenesis of transplanted endothelial progenitor cells in the infarcted myocardium. 2017 , 39, 1347-1356	9
75	Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 2017 , 119, 1401-1406	1
74	The Real Role of β Blockers in Daily Cardiovascular Therapy. 2017 , 17, 361-373	49
73	Meta-Analysis Comparing Metoprolol and Carvedilol on Mortality Benefits in Patients With Acute Myocardial Infarction. 2017 , 120, 1479-1486	11
72	Sympathetic Blockade for Dysrhythmia Management in Heart Failure: Rationale and Therapeutic Progression to Intervention. 2017 ,	
71	An Update on AMPK in Hydrogen Sulfide Pharmacology. 2017 , 8, 810	21
70	Ventricular Arrhythmia after Acute Myocardial Infarction: The Perfect Storm 2017 , 6, 134-139	38
69	Are beta blockers still necessary for all survivors of acute myocardial infarction?. 2017 , 9, 3616-3619	0
68	Hypertension control after an initial cardiac event among Medicare patients with diabetes mellitus: A multidisciplinary group practice observational study. 2018 , 20, 891-901	1
67	Impact of Nontraditional Antiarrhythmic Drugs on Sudden Cardiac Death. 2018 , 1084-1091	
66	Non-ST-Segment Acute Coronary Syndromes. 2018 , 36, 37-52	16
65	Acute Left Ventricular Unloading Reduces Atrial Stretch and Inhibits Atrial Arrhythmias. <i>Journal of the American College of Cardiology</i> , 2018 , 72, 738-750	15.1 17
64	Can Anti-inflammatory Therapy Prevent Atrial Fibrillation in Myocardial Infarction Patients?. 2018 , 59, 3-5	2
63	Failing Hearts Are More Vulnerable to Sympathetic, but Not Vagal Stimulation-Induced, Atrial Fibrillation-Ameliorated with Dantrolene Treatment. 2018 , 24, 460-469	6
62	LCZ696 Therapy Reduces Ventricular Tachyarrhythmia Inducibility in a Myocardial Infarction-Induced Heart Failure Rat Model. 2019 , 2019, 6032631	15
61	Curative effect of β blocker on various ejection fractions of patients with atrial fibrillation. 2019 , 18, 1149-1154	

60	Implications of the transcription factor WT1 linked to the pathologic cardiac remodeling post-myocardial infarction. 2019 , 31, 121-127		1
59	Heart failure as a substrate and trigger for ventricular tachycardia. 2019 , 56, 229-247		17
58	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. 2019 , 140, e125-e151		1020
57	2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. 2019 , 16, e66-e93		176
56	2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 104-132	15.1	807
55	Implications of the transcription factor WT1 linked to the pathologic cardiac remodeling post-myocardial infarction. 2019 , 31, 121-127		2
54	Adjunctive Pharmacologic Therapies in Acute Myocardial Infarction. 2019 , 117-138.e7		1
53	Part 3: Adult Basic and Advanced Life Support: 2020 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. 2020 , 142, S366-S468		251
52	New-onset paroxysmal atrial fibrillation in acute myocardial infarction: increased risk of stroke. 2020 , 10, e039600		3
51	Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. 2020 , 34, 723-735		3
50	Lifestyle and Risk Factor Modification for Reduction of Atrial Fibrillation: A Scientific Statement From the American Heart Association. 2020 , 141, e750-e772		80
49	Carvedilol and metoprolol are both able to preserve myocardial function in type 2 diabetes. 2020 , 8, e14394		2
48	Pharmacological interventions for heart failure in people with chronic kidney disease. 2020 , 2, CD012466		3
47	Statins reduce new-onset atrial fibrillation after acute myocardial infarction: A nationwide study. 2020 , 99, e18517		3
46	Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. 2021 , 12, 625457		2
45	Cytoprotective Potential of Aged Garlic Extract (AGE) and Its Active Constituent, S-allyl-L-cysteine, in Presence of Carvedilol during Isoproterenol-Induced Myocardial Disturbance and Metabolic Derangements in Rats. 2021 , 26,		4
44	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. 2021 , 42, 3727-3738		22
43	Ventricular arrhythmias. Ventricular tachycardias and sudden cardiac death. 2020 Clinical guidelines. 2021 , 26, 4600		9

42	Review of Recent Trials of Medical Therapy for Atrial Fibrillation. 2008 , 147-168		1
41	Una historia resumida. Impacto de los avances en cardiopatía isquémica. 2017 , 17, 2-6		1
40	2020 Clinical practice guidelines for Chronic heart failure. 2020 , 25, 4083		95
39	[Algorithm for the management of patients with stable coronary artery disease and high-grade ventricular arrhythmias]. 2017 , 89, 94-102		7
38	A Critical Review of the Use of Carvedilol in Ischemic Heart Disease. 2012 , 12, 391-401		19
37	Atrial Fibrillation in Patients with Ischemic and Non-Ischemic Left Ventricular Dysfunction. <i>Journal of Atrial Fibrillation</i> , 2013 , 5, 535	0.8	3
36	Atrial Fibrillation in Acute Coronary Syndrome. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 551	0.8	9
35	Sudden death prevention in heart failure: The case of CIBIS III. 2006 , 2, 73		5
34	Effect of Ultra-Short-Acting .BETA.-Blocker Landiolol after Cardiovascular Surgery. 2009 , 38, 179-183		1
33	Class I and III antiarrhythmic drugs for prevention of sudden cardiac death and management of postmyocardial infarction arrhythmias. A review. 2013 , 157, 114-24		4
32	New-Onset Atrial Fibrillation in St-Segment Elevation Myocardial Infarction: Predictors and Impact on Therapy And Mortality. 2019 , 113, 948-957		5
31	Arrhythmias/Palpitations. 2006 , 87-100		
30	Prognosis and Management of Atrial Fibrillation in Different Clinical Settings: Acute Myocardial Infarction. 2006 , 127-130		
29	Heart Attacks. 2006 , 397-431		
28	Ventricular Arrhythmias in Patients After Myocardial Infarction. 2008 , 190-203		
27	Indications for Implantable Cardioverter Defibrillators. 2008 , 495-546		
26	4.?????????????????. 2011 , 31, 365-375		
25	????????????????????(6.????????????????,?76????????????). 2012 , 20, 281-289		

24	Non-antiarrhythmic Drugs in Sudden Death Prevention. 2013 , 525-541		
23	[Prognosis of the life of patients with chronic heart failure and atrial fibrillation, depending on the control of hemodynamic parameters and tolerance to physical exertion in the background of basic therapy]. 2019 , 59, 51-58		2
22	Effect of carvedilol on premature ventricular complexes originating from the ventricular outflow tract. 2020 , 21,		
21	EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ NATIONAL SOCIETY OF HEART FAILURE AND MYOCARDIAL DISEASE (NSHFMD) GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF CHRONIC HEART FAILURE (2020). <i>Eurasian Heart Journal</i> , 2020 , 6-76	0.7	3
20	Perspective on the role of four beta-blockers in heart failure. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , 2021 ,		
19	Executive summary of the African-American Initiative. <i>MedGenMed: Medscape General Medicine</i> , 2007 , 9, 28		3
18	Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation. <i>Cardiovascular Diagnosis and Therapy</i> , 2014 , 4, 28-35	2.6	4
17	Adverse Outcomes from Atrial Fibrillation; Mechanisms, Risks, and Insights Learned from Therapeutic Options. <i>Journal of Atrial Fibrillation</i> , 2012 , 4, 477	0.8	
16	Co-existence of Atrial Fibrillation with Myocardial Infarction - Unhealthy Combination. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 666	0.8	
15	Mortality Risk Associated with AF in Myocardial Infarction Patients. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 554	0.8	1
14	Atrial Fibrillation Complicating Acute Coronary Syndromes. <i>Journal of Atrial Fibrillation</i> , 2012 , 5, 611	0.8	2
13	Beta-blocker treatment in heart failure patients with atrial fibrillation: challenges and perspectives. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 362-375	1.7	
12	Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management. <i>Journal of Geriatric Cardiology</i> , 2021 , 18, 376-397	1.7	
11	JCS 2018 Guideline on Revascularization of Stable Coronary Artery Disease.. <i>Circulation Journal</i> , 2022 , 86,	2.9	3
10	Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
9	Management of Atrial Fibrillation in Patients 75 Years and Older: JACC 'State-of-the-Art' Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 166-179	15.1	3
8	Effect of prior beta-blocker use on in-hospital atrial fibrillation development in patients with ST-elevation myocardial infarction.. <i>Clinical and Experimental Hypertension</i> , 2022 , 1-5	2.2	
7	Cardioselective Versus Nonselective ßBlockers After Myocardial Infarction in Adults With Chronic Obstructive Pulmonary Disease.. <i>Mayo Clinic Proceedings</i> , 2022 ,	6.4	2

- 6 Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs. *Journal of Clinical Medicine*, **2022**, 11, 3233 5.1 ○
- 5 Clinical impact of beta-blockers at discharge on long-term clinical outcomes in patients with non-reduced ejection fraction after acute myocardial infarction. **2022**, ○
- 4 Lifestyle changes in atrial fibrillation management and intervention. ○
- 3 SGLT2 inhibitors reduce sudden cardiac death risk in heart failure: Meta-analysis of randomized clinical trials. ○
- 2 Comparing the Efficacy of Carvedilol and Flecainide on the Treatment of Idiopathic Premature Ventricular Complexes from Ventricular Outflow Tract: A Multicenter, Randomized, Open-Label Pilot Study. **2023**, 12, 2887 ○
- 1 The bidirectional association between atrial fibrillation and myocardial infarction. ○